ArticleEuropean journal of breast health2026
A Rare Entity in Context: Breast Implant-Associated Anaplastic Large Cell Lymphoma Compared With Common Lymphoma Subtypes.
Article in European journal of breast health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare CD30-positive, anaplastic lymphoma kinase (ALK)-negative peripheral T-cell lymphoma now recognized as a distinct entity in the 5 Materials and Methods: Using the Surveillance, Epidemiology and End Results (SEER) database (2017-2022), we identified patients with primary breast lymphoma based on ICD-O-3 site (C50.0-C50.9) and morphology codes for BIA-ALCL (9715/3), diffuse large B-cell lymphoma (DLBCL, 9680/3), extranodal marginal zone [mucosa-associated lymphoid tissue (MALT)] lymphoma (9699/3), and Burkitt lymphoma (BL, 9687/3). Baseline characteristics, treatment, overall survival (OS), and cancer-specific survival (CSS) were compared between BIA-ALCL and other mammary lymphomas. Results: Two hundred fifty-two patients with BIA-ALCL were identified and compared with 185,019 patients with other mammary lymphomas. Patients with BIA-ALCL were younger than those with DLBCL and MALT, but older than those with BL (mean age 62.8 years, Conclusion: In this SEER-based analysis, breast-localized ALK-negative ALCL showed a distinct demographic and treatment profile characterized by surgical management, with favorable crude survival compared with that of DLBCL and BL. Early recognition and complete surgical excision remain central to the management of localized BIA-ALCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.